{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:56:49Z","timestamp":1793224609269,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s11033-021-06888-8","type":"journal-article","created":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T18:04:48Z","timestamp":1638036288000},"page":"827-831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Perspectives of association Baricitinib\/Remdesivir for adults with Covid-19 infection"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2623-166X","authenticated-orcid":false,"given":"Antonio","family":"Vitiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-6783","authenticated-orcid":false,"given":"Francesco","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,27]]},"reference":[{"key":"6888_CR1","unstructured":"World health organization (WHO) (2021) https:\/\/www.who.int\/emergencies\/diseases\/novelcoronavirus2019\/situation-reports (Situation Reports March 2021). Accessed 31 Mar 2021"},{"key":"6888_CR2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","volume":"395","author":"C Wang","year":"2020","unstructured":"Wang C, Horby PW, Hayden FG, Gao GF (2020) A novel coronavirus outbreak of global health concern. Lancet 395:470\u2013473","journal-title":"Lancet"},{"issue":"2020","key":"6888_CR3","first-page":"497","volume":"395","author":"C Huang","year":"2019","unstructured":"Huang C et al (2019) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(2020):497\u2013506","journal-title":"Lancet"},{"key":"6888_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-021-02584-5","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Porta R, Pianesi L, Ferrara F (2021) COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view. Ir J Med Sci. https:\/\/doi.org\/10.1007\/s11845-021-02584-5","journal-title":"Ir J Med Sci"},{"key":"6888_CR5","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li Q et al (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus- infected pneumonia. N Engl J Med 382:1199\u20131207","journal-title":"N Engl J Med"},{"issue":"2020","key":"6888_CR6","first-page":"727","volume":"382","author":"N Zhu","year":"2019","unstructured":"Zhu N et al (2019) A novel coronavirus from patients with pneumonia in China. N Engl J Med 382(2020):727\u2013733","journal-title":"N Engl J Med"},{"key":"6888_CR7","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.07.937862","author":"AE Gorbalenya","year":"2020","unstructured":"Gorbalenya AE et al (2020) Severe acute respiratory syndrome-related coronavirus: the species and its viruses \u2013 a statement of the coronavirus study group. Microbiology. https:\/\/doi.org\/10.1101\/2020.02.07.937862","journal-title":"Microbiology"},{"key":"6888_CR8","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/ajcp\/aqaa029","volume":"153","author":"J Guarner","year":"2020","unstructured":"Guarner J (2020) Three emerging coronaviruses in two decades. Am J Clin Pathol 153:420\u2013421","journal-title":"Am J Clin Pathol"},{"key":"6888_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106322","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Ferrara F (2021) Colchicine and SARS-CoV-2: management of the hyperinflammatory state. Respir Med. https:\/\/doi.org\/10.1016\/j.rmed.2021.106322","journal-title":"Respir Med"},{"key":"6888_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2021.01.007","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, LaPorta R, D\u2019Aiuto V, Ferrara F (2021) Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Human Immunol. https:\/\/doi.org\/10.1016\/j.humimm.2021.01.007","journal-title":"Human Immunol"},{"issue":"2","key":"6888_CR11","first-page":"88","volume":"14","author":"A Vitiello","year":"2020","unstructured":"Vitiello A, Ferrara F, Pelliccia C, Granata G, La Porta R (2020) Cytokine storm and colchicine potential role in fighting SARS-CoV-2 pneumonia. Ital J Med 14(2):88\u201394","journal-title":"Ital J Med"},{"issue":"883","key":"6888_CR12","doi-asserted-by":"publisher","first-page":"173373","DOI":"10.1016\/j.ejphar.2020.173373","volume":"15","author":"A Vitiello","year":"2020","unstructured":"Vitiello A, Ferrara F (2020) Correlation between renin-angiotensin system and severe acute respiratory syndrome coronavirus 2 infection: what do we know? Eur J Pharmacol 15(883):173373. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173373","journal-title":"Eur J Pharmacol"},{"key":"6888_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.01.010","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Pelliccia C, Ferrara F (2021) Drugs acting on the renin\u2013angiotensin system and SARS-CoV-2. Drug Discov Today. https:\/\/doi.org\/10.1016\/j.drudis.2021.01.010","journal-title":"Drug Discov Today"},{"issue":"156","key":"6888_CR14","doi-asserted-by":"publisher","first-page":"105579","DOI":"10.1016\/j.ejps.2020.105579","volume":"1","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Ferrara F (2021) Therapeutic strategies for SARS-CoV-2 acting on ACE-2. Eur J Pharm Sci 1(156):105579. https:\/\/doi.org\/10.1016\/j.ejps.2020.105579","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"6888_CR15","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00228-020-02947-4","volume":"76","author":"F Ferrara","year":"2020","unstructured":"Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A (2020) The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol 76(11):1615\u20131618. https:\/\/doi.org\/10.1007\/s00228-020-02947-4","journal-title":"Eur J Clin Pharmacol"},{"issue":"262","key":"6888_CR16","doi-asserted-by":"publisher","first-page":"118510","DOI":"10.1016\/j.lfs.2020.118510","volume":"1","author":"A Vitiello","year":"2020","unstructured":"Vitiello A, Ferrara F (2020) Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci 1(262):118510. https:\/\/doi.org\/10.1016\/j.lfs.2020.118510","journal-title":"Life Sci"},{"key":"6888_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2020-111497","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, La Porta R, Ferrara F (2021) Sacubitril, valsartan and SARS-CoV-2. BMJ Evid Based Med. https:\/\/doi.org\/10.1136\/bmjebm-2020-111497","journal-title":"BMJ Evid Based Med"},{"key":"6888_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-021-02049-7","author":"F Ferrara","year":"2021","unstructured":"Ferrara F, Vitiello A (2021) Efficacy of synthetic glucocorticoids in COVID-19 endothelites. Naunyn-Schmiedeberg Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-021-02049-7","journal-title":"Naunyn-Schmiedeberg Arch Pharmacol"},{"issue":"7","key":"6888_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/phar.2429","volume":"40","author":"SCJ Jorgensen","year":"2020","unstructured":"Jorgensen SCJ, Kebriaei R, Dresser LD (2020) Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacotherapy 40(7):659\u2013671. https:\/\/doi.org\/10.1002\/phar.2429","journal-title":"Pharmacotherapy"},{"key":"6888_CR20","doi-asserted-by":"publisher","first-page":"101615","DOI":"10.1016\/j.tmaid.2020.101615","volume":"34","author":"JA Al-Tawfiq","year":"2020","unstructured":"Al-Tawfiq JA, Al-Homoud AH, Memish ZA (2020) Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis 34:101615. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101615","journal-title":"Travel Med Infect Dis"},{"key":"6888_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-020-02482-2","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Ferrara F, La Porta R (2021) Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. https:\/\/doi.org\/10.1007\/s11845-020-02482-2","journal-title":"Ir J Med Sci"},{"issue":"9","key":"6888_CR22","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1473-3099(20)30262-0","volume":"20","author":"EG Favalli","year":"2020","unstructured":"Favalli EG, Biggioggero M, Maioli G, Caporali R (2020) Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis 20(9):1012\u20131013. https:\/\/doi.org\/10.1016\/S1473-3099(20)30262-0","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"6888_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/phar.2438","volume":"40","author":"SCJ Jorgensen","year":"2020","unstructured":"Jorgensen SCJ, Tse CLY, Burry L, Dresser LD (2020) Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy 40(8):843\u2013856. https:\/\/doi.org\/10.1002\/phar.2438","journal-title":"Pharmacotherapy"},{"key":"6888_CR24","doi-asserted-by":"publisher","DOI":"10.4081\/itjm.2020.1435","author":"F Ferrara","year":"2020","unstructured":"Ferrara F, Vitiello A (2020) Potential pharmacological approach in the regulation of ACE-2 and DPP-IV in diabetic COVID-19 patient. Ital J Med. https:\/\/doi.org\/10.4081\/itjm.2020.1435","journal-title":"Ital J Med"},{"key":"6888_CR25","doi-asserted-by":"publisher","first-page":"110486","DOI":"10.1016\/j.mehy.2021.110486","volume":"147","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, La Porta R, Ferrara F (2021) Scientific hypothesis and rational pharmacological for the use of sacubitril\/valsartan in cardiac damage caused by COVID-19. Med Hypotheses 147:110486","journal-title":"Med Hypotheses"},{"key":"6888_CR26","doi-asserted-by":"publisher","first-page":"ciaa879","DOI":"10.1093\/cid\/ciaa879","volume":"29","author":"BK Titanji","year":"2020","unstructured":"Titanji BK, Farley MM, Mehta A, Connor-Schuler R, Moanna A, Cribbs SK et al (2020) Use of Baricitinib in patients with moderate and severe COVID-19. Clin Infect Dis 29:ciaa879. https:\/\/doi.org\/10.1093\/cid\/ciaa879","journal-title":"Clin Infect Dis"},{"key":"6888_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.11.007","author":"TN Hoang","year":"2021","unstructured":"Hoang TN, Pino M, Boddapati AK, Viox EG, Starke CE, Upadhyay AA et al (2021) Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Cell. https:\/\/doi.org\/10.1016\/j.cell.2020.11.007","journal-title":"Cell"},{"key":"6888_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11845-020-02401-5","volume":"17","author":"F Ferrara","year":"2020","unstructured":"Ferrara F, Porta R, D\u2019Aiuto V, Vitiello A (2020) Remdesivir and COVID-19. Ir J Med Sci 17:1\u20132. https:\/\/doi.org\/10.1007\/s11845-020-02401-5","journal-title":"Ir J Med Sci"},{"key":"6888_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11845-020-02440-y","volume":"18","author":"A Vitiello","year":"2020","unstructured":"Vitiello A, Ferrara F (2020) Remdesivir versus ritonavir\/lopinavir in COVID-19 patients. Ir J Med Sci 18:1\u20132. https:\/\/doi.org\/10.1007\/s11845-020-02440-y","journal-title":"Ir J Med Sci"},{"issue":"11","key":"6888_CR30","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1001\/jama.2020.16337","volume":"324","author":"EK McCreary","year":"2020","unstructured":"McCreary EK, Angus DC (2020) Efficacy of Remdesivir in COVID-19. JAMA 324(11):1041\u20131042. https:\/\/doi.org\/10.1001\/jama.2020.16337","journal-title":"JAMA"},{"key":"6888_CR31","doi-asserted-by":"publisher","first-page":"106749","DOI":"10.1016\/j.intimp.2020.106749","volume":"86","author":"X Zhang","year":"2020","unstructured":"Zhang X, Zhang Y, Qiao W, Zhang J, Qi Z (2020) Baricitinib a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Int Immunopharmacol 86:106749. https:\/\/doi.org\/10.1016\/j.intimp.2020.106749","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"6888_CR32","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V et al (2021) ACTT-2 study group members Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N Engl J Med 384(9):795\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa2031994","journal-title":"N Engl J Med"},{"issue":"6","key":"6888_CR33","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"H Pan","year":"2021","unstructured":"WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hern\u00e1ndez Garc\u00eda C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, Garc\u00eda PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portol\u00e9s A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, R\u00f8ttingen JA, Swaminathan S (2021) Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results. N Engl J Med 384(6):497\u2013511. https:\/\/doi.org\/10.1056\/NEJMoa2023184","journal-title":"N Engl J Med"},{"issue":"19","key":"6888_CR34","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, F\u00e4tkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, ACTT-1 Study Group Members (2020) Remdesivir for the treatment of Covid-19 - Final report. N Engl J Med 383(19):1813\u20131826. https:\/\/doi.org\/10.1056\/NEJMoa2007764","journal-title":"N Engl J Med"},{"issue":"5","key":"6888_CR35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.4103\/ijp.IJP_417_20","volume":"52","author":"F Ferrara","year":"2020","unstructured":"Ferrara F, Porta R, Santilli P, DAiuto V, Vitiello A, (2020) Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times? Indian J Pharmacol 52(5):441\u2013442. https:\/\/doi.org\/10.4103\/ijp.IJP_417_20","journal-title":"Indian J Pharmacol"},{"key":"6888_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s43066-021-00082-y","volume":"11","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, La Porta R, D\u2019Aiuto V et al (2021) The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced. Egypt Liver J 11:11. https:\/\/doi.org\/10.1186\/s43066-021-00082-y","journal-title":"Egypt Liver J"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06888-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-021-06888-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06888-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T14:42:02Z","timestamp":1641825722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-021-06888-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,27]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["6888"],"URL":"https:\/\/doi.org\/10.1007\/s11033-021-06888-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,27]]},"assertion":[{"value":"28 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors consent to the publication of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}